Tebchaws Meskas Tuaj Tebchaws, Tebchaws Thoob Plaws Hauv Tebchaws Asmeskas, Lub Tebchaws Thoob Plaws Tebchaws Thoob Plaws Tebchaws

Osimertinib (AZD-9291) hmoov

Rating:
5.00 tawm ntawm 5 raws li nyob rau 1 neeg ntsuam xyuas
SKU: 1421373-65-0. Qeb:

AASraw yog nrog synthesis thiab muaj peev xwm ua tau los ntawm cov gram los ntawm huab hwm coj ntawm Osimertinib (AZD-9291) hmoov (1421373-65-0), raws li CGMP kev tswj thiab kev tswj xyuas qhov system.

Osimertinib (AZD-9291) hmoov yog ib lub qhov ncauj, tsis tshua muaj kev txhawj xeeb ntawm cov tshuaj tua kab mob hauv lub cev (EGFR) thiab cov T790M kuj hloov tau tus kheej (IC50s = 15-17 nM) thaum sparing daim ntawv qus hom ntawm lub receptor (IC50 = 480 nM) .1 nws khi cov IGF1R Thiab HERG receptors nrog implantency txo (IC50s = 2.9 thiab 16.2 μM, feem). 1 AZD 9291 tau pom tias inhibit qog loj hlob hauv xenograft nas qauv ntawm qhov ncauj ntawm 5-10 mg / kg thiab tau raug soj ntsuam nyob hauv cov neeg mob siab EGFR mutant non-me-mob ntsws cancer.

Hauj lwm yam khoom

Osimertinib (AZD-9291) hmoov video


Osimertinib (AZD-9291) hmoov theem pib

Lub npe: Osimertinib (AZD-9291) hmoov
CAS: 1421373-65-0
Molecular Formula: C28H33N7O2
Molecular phaus: 499.61
Melt Point: > 188ºC
Cia Temp: -20 ° C
xim: Lub teeb daj hmoov cov hmoov


Osimertinib (AZD-9291) hmoov hauv kev siv

lub npe

AZD-9291 powder (CAS 1421373-65-0), N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide

AZD-9291 Hmoov siv

AZD-9291 hmoov muab ib zaug txhua hnub ntawm qhov ncauj ntawm 5 mg / kg los ua qhov kev txhawj xeeb ntawm cov hlav thoob EGFRm + (PC9; 178% kev loj hlob inhibition) thiab EGFRm + / T790M (H1975; 119% kev loj hlob inhibition) qog qauv hauv vivo,
tom qab 14 hnub noj tshuaj. Txuas ntxiv 5 mg / kg AZD-9291 hmoov yog txaus ua rau lub zog ntswj ntawm EGFRm + thiab EGFRm + T790M transgenic nas ntsws qog. Kev loj hlob hauv kev loj hlob yog ua rau muaj kev lim dej ntawm EGFR phosphorylation thiab cov qhov tseem ceeb hauv cov nqes taw qhia xws li AKT thiab ERK. Kev kho mob ntev mus ntev ntawm PC9 thiab H1975 xenograft hlav nrog AZD-9291 hmoov coj mus ua tiav thiab muaj lub siab ua teb, uas tsis pom hlav tom qab 40 hnub noj tshuaj, thiab ua nyob dhau hnub 100 hnub. Txuas ntxiv, pre-clinical cov ntaub ntawv kuj qhia tau hais tias AZD-9291 hmoov yuav hom nqaij hlav uas tau nrhiav tsis tau mus rau ntau lub npe tshiab HER2-amplification mechanism, yog li muaj feem ncua txuas nws cov txiaj ntsig hauv TKI resistant cov neeg mob.

Ceeb toom rau AZD-9291 hmoov

AZD-9291 hmoov (CAS 1421373-65-0) yog tsuas tshuaj pom zoo rau cov neeg mob uas tau siv cov tshuaj EGFR T790M hloov mus rau cov neeg tsis muaj zog ntawm lub ntsws cancer. Qhov kev qhia no tau pom zoo los ntawm FDA qhov kev pom zoo los ntawm kev pom zoo los ntawm kev mob tebchaw thiab lub sijhawm teb (DoR).

Cov kab mob tshwm sim muaj xws li mob plab, mob stomatitis, ua pob txha, los yog khaus khaus tawv nqaij, kab mob qhov twg ntiv tes los yog ntiv taw siv tawv nqaij, platelet qis, qis leukocyte suav, thiab qis neutrophil suav.
Tsis muaj kev tsis sib haum xeeb rau TAGRISSO
Kabmob Ntshav Rau Kabmob Ntshav (ILD) / Pneumonitis tau tshwm sim nyob rau hauv 3.3% thiab raug tuag hauv 0.5% ntawm 813 TAGRISSO cov neeg mob. Txiav TAGRISSO thiab soj ntsuam kom sai rau ILD hauv ib tus neeg mob uas tuaj yeem ua phem rau cov kev mob ntsws ntawm lub cev uas qhia tau tias muaj ILD (xws li, mob nyhav, hnoos thiab ua npaws). Tsis tuaj yeem tsum TAGRISSO yog tias ILD raug pom zoo
QTP tau luv lub sij hawm nyob rau hauv cov neeg mob TAGRISSO. Ntawm cov 411 cov neeg mob hauv kev tshawb nrhiav Phase II, ib tus neeg mob (0.2%) tau pom tias muaj QTc ntau dua 500 msec, thiab 11 cov neeg mob (2.7%) tau nce ntawm QEEC ntau tshaj li 60 msec. Ua rau lub sijhawm sojntsuam nrog ECGs thiab electrolytes rau cov neeg mob uas muaj tus kabmob qog QTC, congestive heart failure, electrolyte abnormalities, lossis cov neeg noj tshuaj uas paub tias yuav ua kom ntev npaum li QTc lub sijhawm. Tsis tu ncua TAGRISSO rau cov neeg mob uas tsim QTc tau ntev mus ntev nrog cov paib / cov tsos mob ntawm lub neej yuav ua teeb meem arrhythmia
Cardiomyopathy tau tshwm sim hauv 1.4% thiab raug tuag hauv 0.2% ntawm 813 TAGRISSO cov neeg mob. Left Ventricular Ejection Fraction (LVEF) poob> 10% thiab poob rau <50% tshwm sim nyob rau hauv 2.4% ntawm (9 / 375) TAGRISSO cov neeg mob. Soj ntsuam LVEF ua ntej pib thiab tom 3 lub hlis cov kev kho mob. Txiav TAGRISSO yog tias ejection feem zuj zus los ntawm 10% los ntawm kev tsim nqi thiab qhov tsawg dua 50%. Rau kev mob plawv tsis ua hauj lwm los yog mob asymptomatic LV kawg uas tsis kho hauv 4 lub lis piam, tsis tuaj yeem tsum tsis tu ncua TAGRISSO.
Qhia tawm cov poj niam cev xeeb tub ntawm cov kev pheej hmoo rau tus me nyuam hauv plab. Qhia cov pojniam ntawm kev ua me nyuam siv cov tshuaj tiv thaiv zoo thaum lub sij hawm TAGRISSO kho mob thiab rau 6 lub lis piam tom qab kawg koob tshuaj. Qhia cov txiv neej nrog cov poj niam koom tes ntawm kev muaj peev xwm tuaj yeem siv tshuaj tiv thaiv zoo rau 4 lub hlis tom qab kawg koob.
Feem ntau cov kev phiv tshuaj (> 20%) uas pom hauv TAGRISSO cov neeg mob tau mob raws plab (42%), pob xaws (41%), qhuav ntawm daim tawv nqaij (31%) thiab tshuaj lom toxicity (25%).

Cov lus qhia ntxiv

AZD-9291 hmoov yog mob siab heev hauv cov neeg mob uas mob ntsws cancer nrog EGFR T790M hloov uas tau muaj mob rau lub sijhawm ua ntej kho nrog EGFR tyrosine kinase inhibitors.

AZD-9291 hmoov yog kawm nyob rau hauv qhov kev tshawb fawb, AURA3, qhib daim ntawv lo, randomized Phase III txoj kev tshawb nrhiav tsim los ntsuam xyuas txoj kev txuag thiab kev nyab xeeb ntawm AZD-9291 hmoov tiv thaiv platinum-based doublet chemotherapy rau cov neeg mob EGFR T790M zoo, los yog metastatic NSCLC uas tau muaj mob ua ntej ua ntej txoj kev kho nrog EGFR-TKI. AZD-9291 hmoov kuj tseem raug tshawb fawb hauv qhov chaw nyob thiab qhov teeb meem hauv thawj qhov chaw metastatic, nrog rau cov neeg mob hlwb, nrog rau lwm lub tebchaw.

AZD-9291 Hmoov 80mg ib zaug ib hnub yog ib qho tshuaj thawj zaug uas qhia rau cov neeg mob uas muaj tus kab mob hu ua metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell ntsws cancer (NSCLC), raws li tau pom los ntawm FDA-pom zoo kuaj, uas tau nce mus rau lossis tom qab kho EGFR tyrosine kinase inhibitor (TKI). Cov kev tshawb fawb hauv vitro pom tau tias AZD-9291 hmoov muaj siab muaj zog thiab tiv thaiv tsis tau cov kab mob EGFR phosphorylation hauv cov kab mob EGFRm thiab T790M mutant NSCLC cell kab nrog tsawg ho ua txhaum tawm tsam EGFR hauv cov qe-hom kab ntawm tes.

Osimertinib hmoov tau tsis ntev los no tau luam tawm los ntawm World Health Organization (WHO) raws li lub tswv yim International Non-proprietary Name (INN) rau cov hmoov AZD-9291, thiab tej zaum yuav ua raws cai thaum lub Kaum Ib Hlis 2015. Hauv Tebchaws Asmeskas, American Medical Association txais Osimertinib hmoov li lub Tebchaws Asmeskas Tuam Txhab (USAN).

AZD-9291 hmoov (CAS 1421373-65-0)

Min yuam 10grams.
Cov lus nug txog ntawm ntau npaum li cas (Hauv 1kg) tuaj yeem xa tawm hauv 12 teev tom qab them nyiaj.
Rau kev loj dua (Hauv 1kg) tuaj yeem xa tawm hauv 3 hnub ua hauj lwm tom qab them nyiaj.

Caffeic Acid Phenethyl Ester Marketing

Kom muab rau yav tom ntej tom ntej.


Yuav ua li cas yuav Osimertinib hmoov; yuav AZD-9291 hmoov (CAS 1421373-65-0) los ntawm AASraw

1.To tiv tauj peb ntawm peb tus email nug qhov system, lossis hauv internettus sawv cev rau tus neeg sawv cev (CSR).
2.To muab peb nug koj qhov ntau thiab qhov chaw nyob.
3.Our CSR yuav muab nqe lus hais txog koj, qhov them nqi, tus lej nrhiav, kev xaib thiab kwv yees hnub uas tuaj txog (ETA).
4.Payment ua tiav thiab cov khoom xa tuaj rau 12 cov xuab moos (Rau kev txiav txim hauv 10kg).
5.Goods tau txais thiab muab tswv yim.

PRECAUTION THIAB DISCLAIMER:

Cov Khoom Siv No Yog Muag Rau Kev Tshawb Xyuas Siv Xwb. Cov ntsiab lus ntawm kev muag khoom Thov. Tsis Yog Rau Tib Neeg Noj, Tsis Kho Mob, Kho Tsiaj, lossis Tsev Neeg Siv.


COA

COA 1421373-65-0 Osimertinib (AZD-9291) AASRAW

HNMR

Zaub mov txawv

Caffeic Acid Phenethyl Ester Hmoov Noj Txawv Noj

Yog xav paub txog peb Tus Neeg Sawv Cev Kev Nkag Siab (CSR) kom paub meej, rau qhov koj siv.

References & cov khoom citations